Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Cannabidiol as an Add-On Treatment for Patients with Severe Alcohol Use Disorder During Inpatient Alcohol Cessation

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of severe Alcohol Use Disorder, a condition where individuals have a strong urge to drink alcohol despite negative consequences. The study will explore the use of cannabidiol, also known as CBD, as an additional treatment to help patients who are trying to stop drinking alcohol during a planned hospital stay. The medication being tested is called Arvisol 150mg, and it will be compared to a placebo to see if it helps maintain abstinence from alcohol.

The purpose of the study is to see if using CBD can help patients stay away from alcohol for a longer period after they leave the hospital. Participants will take part in the study for about six weeks, starting with their hospital stay and continuing for a month after they are discharged. During this time, they will receive either the CBD treatment or a placebo. The study will involve regular check-ups to monitor their progress and any side effects they might experience.

Throughout the study, participants will be asked to report their alcohol use and any symptoms they experience. This information will help researchers understand if CBD can effectively support people in maintaining their abstinence from alcohol. The study aims to provide valuable insights into whether CBD can be a helpful addition to traditional treatments for severe Alcohol Use Disorder.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be hospitalized for a scheduled alcohol cessation program. This is a necessary step to ensure a controlled environment for the trial.

  2. Step 2

    Medication administration

    During your stay, you will receive a tablet called Arvisol 150mg or a placebo. This will be administered orally. The exact dosage and frequency will be determined by the study team based on your specific needs.

  3. Step 3

    Daily assessments

    From day 0 to day 10, you will undergo daily assessments. These include self-reports of alcohol abstinence, symptoms checklists for side effects, and evaluations of alcohol withdrawal and craving levels.

  4. Step 4

    Urinary assessments

    During your inpatient stay, two urinary assessments will be conducted to check for signs of alcohol use. These assessments will continue weekly after discharge up to week 6.

  5. Step 5

    Outpatient visits

    After discharge, you will have four outpatient visits, one per week, up to week 6. During these visits, you will continue to report on alcohol use, undergo clinical examinations, and complete various scales to assess anxiety, sleep quality, and other factors.

  6. Step 6

    Final assessments

    At the end of week 6, a final assessment will be conducted to evaluate your abstinence maintenance and overall progress in the study.

Who can join the trial?

7 criteria

  • Patients must be hospitalized for a planned stay to stop alcohol use.
  • Patients should be between 18 and 75 years old.
  • Patients must meet the criteria for severe Alcohol Use Disorder (AUD) as defined by the DSM 5, which is a guide used by healthcare professionals to diagnose mental disorders.
  • Patients must be willing to participate in the study.
  • Patients need to sign a written informed consent, which means they agree to participate after being informed about the study.
  • Patients must have current social insurance.
  • Females of childbearing age must use an effective method of birth control during the treatment and for up to seven days after the treatment ends.

Who cannot join the trial?

1 criterion

  • Patients with **severe Alcohol Use Disorder**. This means having a serious problem with alcohol, as defined by a specific set of guidelines called DSM 5.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Cannabidiol is a compound that comes from the cannabis plant. In this trial, it is being used as an additional treatment to help people who are trying to stop drinking alcohol. The goal is to see if it can help patients stay away from alcohol for a longer time after they leave the hospital. Cannabidiol is not the part of cannabis that makes you feel "high," but it might have other effects that could support people in their recovery from alcohol use disorder.

What is already known about the treatment

Cannabidiol – Cannabidiol, often referred to as CBD, is administered orally and is being studied as an additional treatment for patients with severe Alcohol Use Disorder who are undergoing inpatient alcohol cessation. Currently, CBD is gaining attention in medical literature for its potential benefits in various conditions, including substance use disorders. The main therapeutic indication in this trial is to help maintain abstinence from alcohol after discharge from an inpatient stay. At the molecular level, CBD interacts with the body's endocannabinoid system, which may help regulate mood and cravings. It is classified pharmacologically as a cannabinoid, a type of compound found in cannabis plants.

Investigated diseases

Alcohol Use Disorder – Alcohol Use Disorder is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It progresses through various stages, starting with increased tolerance and leading to dependence, where the individual experiences withdrawal symptoms when not consuming alcohol. Over time, the disorder can lead to significant physical and psychological issues, including liver damage, cardiovascular problems, and cognitive impairments. The progression often involves a cycle of excessive drinking, attempts to quit, and relapses. As the disorder advances, individuals may experience a loss of control over their drinking habits and a preoccupation with alcohol. The condition can severely impact daily functioning and relationships.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-518455-28-00Protocol codeAPHP180619Estimated enrolment210 patientsSponsorAssistance Publique Hopitaux De Paris

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.